US-based surgical automation technology and software provider Caresyntax received $45.6m in funding from investors including diversified trading group Mitsubishi Corporation, healthcare imaging technology producer Barco Healthcare and insurance firm Relyens yesterday.
The round was also backed by Drug Discovery Gateway, the investment partnership formed by pharmaceutical firm Takeda and alternative asset manager Whiz Partners, as well as Plug and Play, IPF Partners and Caresyntax’s founders
Caresyntax’s platform combines artificial intelligence, data analytics and internet-of-things technology to help surgical teams automate clinical decisions. Its partners include both Barco and Mitsubishi subsidiary MC Healthcare.
Filip Pintelon, general manager of healthcare for Barco, said: “Through our partnership with Caresyntax, we intend to expand the Barco Nexxis solution for digital operating rooms with Caresyntax surgical automation and AI technologies to improve overall surgical decision making, efficiency and performance.”
Pharmaceutical company Norgine had provided $11.9m in funding for the company in September 2017 through its Norgine Ventures subsidiary, before surgery-focused investment fund Surgical.AI added $20m in June 2018 to close its first round.
Pierre-Yves Antier, Releyens’ head of strategy, innovation and transformation, said: “Caresyntax has created a unique, proprietary platform that enables insurers like Relyens to leverage real-world data to offer complete, tailor-made risk management solutions to our clients.
“We deeply admire Caresyntax’s leading team of expert professionals and are proud to support the company as they continue to execute on their mission.”
